People with conditions the drugs are approved to treat get sent back to Part D, where copays can hit $200 to $600 a month. One New Jersey patient was rejected despite a BMI of 42.
Recap by typeshit. Full story at Sleep Review.
Costco is adding Novo Nordisk's semaglutide shots to what it offers. Details are thin here, so tap through for how pricing and access will work.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Now CMO at CORXEL, Liang tells PharmExec he sees GLP-1s as a platform for heart, kidney and liver disease, with obesity only one piece of it.
The Wall Street Journal traces how suppliers tied to fentanyl precursors have moved into selling gray-market peptides to American buyers.
Loading…